NYSE$LLY
Eli Lilly & Co · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Eli Lilly's financial performance for Q1 2020 was released, showing a strong increase in revenue driven by volume growth and augmented by COVID-19 related buying patterns, with EPS decreasing on a reported basis but increasing on a non-GAAP basis, and EPS guidance was adjusted.
Eli Lilly reported a strong first quarter with a 15% increase in revenue, driven by a 22% increase in volume. The company's performance was augmented by increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic, which added approximately $250 million to revenue. EPS decreased on a reported basis but increased to $1.75 on a non-GAAP basis. The company has adjusted its EPS guidance for 2020.
- Revenue increased by 15%, driven by a 22% volume growth, with COVID-19 related buying patterns adding approximately $250 million.
- Key growth products launched since 2014 contributed 19 percentage points of revenue growth, representing approximately 51% of total revenue.
- Operating expenses grew by 7%, driven by increased investments in R&D.
- EPS decreased to $1.60 on a reported basis, but increased to $1.75 on a non-GAAP basis.
Headline financials
Revenue & EPS history
Eli Lilly · Revenue · Quarterly
$5.86B
Revenue by segment
Eli Lilly · $2.45B total across 2 segments · Q3 2023
- Mounjaro$1.41B+652.4%57.5%
- Verzenio$1.04B+68.4%42.5%
Forward guidance
Eli Lilly has updated its 2020 financial guidance, reflecting both management's expectations for operational performance and the uncertainty surrounding the extent and duration of the impact of the COVID-19 pandemic. Earnings per share for 2020 is now expected to be in the range of $6.20 to $6.40 on a reported basis and $6.70 to $6.90 on a non-GAAP basis.
Tailwinds
- Increased customer buying patterns and patient prescription trends associated with COVID-19 that were experienced in the first quarter of 2020 will largely be reversed over the course of 2020.
- The reduction in new-to-brand prescription trends will peak in the second quarter of 2020 in the U.S. and much of Europe.
- Healthcare activity, including non-COVID-19 related patient visits with their physicians, will align more closely with historical levels in the second half of 2020.
- Clinical trial enrollment in existing studies, as well as initiation of new clinical trials, will resume in the second half of 2020.
- Investment in COVID-19 related research, testing and support will continue throughout 2020.
Headwinds
- Increased utilization of patient affordability programs will negatively impact U.S. pricing.
- Changes in segment mix due to increased U.S. unemployment will negatively impact U.S. pricing.
- Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity.
- Revenue growth is also expected to be partially offset by a low-single digit net price decline in the U.S., driven primarily by rebates and legislated increases to Medicare Part D cost sharing.
- Net price declines are expected in China, Japan and Europe.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+3.1%
Avg return
30 days after
43%
29 / 67 earnings
Positive
+15.9%
Q2 2023
Best reaction
-14.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +16.2% | +29.9% | |
| Q4 2025 | +10.3% | +4.1% | -1.3% | |
| Q3 2025 | +3.2% | +11.5% | +32.2% | |
| Q2 2025 | -14.1% | -14.3% | -2.6% | |
| Q1 2025 | -11.7% | -13.8% | -17.9% | |
| Q4 2024 | +3.3% | +2.7% | +3.3% | |
| Q3 2024 | -8.2% | -10.8% | -12.0% | |
| Q2 2024 | +15.5% | +17.6% | +16.9% | |
| Q1 2024 | +5.4% | -0.3% | +10.6% | |
| Q4 2023 | +2.7% | +4.8% | +10.5% | |
| Q3 2023 | +2.4% | +8.2% | +5.3% | |
| Q2 2023 | +15.9% | +16.3% | +26.2% | |
| Q1 2023 | +5.2% | +7.4% | +13.2% | |
| Q4 2022 | -1.0% | -0.8% | -7.0% | |
| Q3 2022 | -2.0% | -1.3% | +2.3% | |
| Q2 2022 | -4.0% | -3.4% | -4.0% | |
| Q1 2022 | +2.5% | +1.0% | +13.5% | |
| Q4 2021 | -3.4% | -4.4% | +4.8% | |
| Q3 2021 | +2.1% | +4.0% | +6.9% | |
| Q2 2021 | +6.4% | +6.8% | +5.3% | |
| Q1 2021 | -3.6% | -2.4% | +6.4% | |
| Q4 2020 | -3.3% | -6.3% | -2.5% | |
| Q3 2020 | -7.3% | -7.9% | +2.2% | |
| Q2 2020 | -7.1% | -4.3% | -8.9% | |
| Q1 2020 | +4.0% | +0.4% | -3.5% | |
| Q4 2019 | -0.2% | +2.5% | -9.9% | |
| Q3 2019 | -1.8% | +2.9% | +5.8% | |
| Q2 2019 | +0.2% | +3.4% | +3.2% | |
| Q1 2019 | -1.2% | -2.2% | -3.1% | |
| Q4 2018 | -2.4% | -2.0% | +5.2% | |
| Q3 2018 | -0.4% | +1.9% | +5.2% | |
| Q2 2018 | +8.5% | +8.7% | +17.9% | |
| Q1 2018 | +1.2% | +3.2% | +3.1% | |
| Q4 2017 | -4.3% | -10.0% | -10.3% | |
| Q3 2017 | -2.7% | -3.8% | -4.0% | |
| Q2 2017 | -3.4% | -1.9% | -6.9% | |
| Q1 2017 | -2.9% | -1.6% | -6.1% | |
| Q4 2016 | +3.9% | +3.4% | +11.0% | |
| Q3 2016 | -1.0% | -3.9% | -12.3% | |
| Q2 2016 | +1.7% | +1.1% | -4.8% | |
| Q1 2016 | -1.8% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | +1.7% | — | — | |
| Q2 2015 | -1.9% | — | — | |
| Q1 2015 | -1.0% | — | — | |
| Q4 2014 | -0.6% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -0.7% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q3 2013 | +0.8% | — | — | |
| Q2 2013 | +3.1% | — | — | |
| Q1 2013 | -3.3% | — | — | |
| Q4 2012 | +2.9% | — | — | |
| Q3 2012 | -1.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +2.3% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | -1.9% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2010 | -0.3% | — | — | |
| Q2 2010 | +2.5% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q4 2009 | -0.8% | — | — | |
| Q4 2008 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro